Data as of Mar 12
| +0.03 / +0.75%|
The 5 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 5.00, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +24.07% increase from the last price of 4.03.
The current consensus among 5 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.